UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression

The American journal of psychiatry, 2008-05, Vol.165 (5), p.617-620

2008

Volltextzugriff (PDF)

Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders

Australian and New Zealand journal of psychiatry, 2010-08, Vol.44 (8), p.697-705

2010

Volltextzugriff (PDF)

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

The AAPS journal, 2022-01, Vol.24 (1), p.19-19, Article 19

2022

Volltextzugriff (PDF)

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Journal of clinical psychopharmacology, 2008-12, Vol.28 (6), p.631-637

2008

Volltextzugriff (PDF)

A Confidence Interval for the Maximal Mean QT Interval Change Caused by Drug Effect

Therapeutic innovation & regulatory science, 2006-07, Vol.40 (3), p.267-271

2006

Volltextzugriff (PDF)

Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression: Did Baseline Characteristics Impact Trial Outcome?

Journal of clinical psychopharmacology, 2012-08, Vol.32 (4), p.470-478

2012

Volltextzugriff (PDF)

Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial

The journal of clinical psychiatry, 2014-03, Vol.75 (3), p.e184

2014

Volltextzugriff (PDF)

Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials

The journal of clinical psychiatry, 2012-06, Vol.73 (6), p.e742

2012

Volltextzugriff (PDF)

Comparative efficacy of antidepressants in preventing relapse in anxiety disorders — A meta-analysis

Journal of affective disorders, 2010-06, Vol.123 (1), p.9-16

2010

Volltextzugriff (PDF)

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial

The journal of clinical psychiatry, 2012-11, Vol.73 (11), p.1412

2012

Volltextzugriff (PDF)

Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis

Journal of pharmacokinetics and pharmacodynamics, 2016-06, Vol.43 (3), p.325-341

2016

Volltextzugriff (PDF)

Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, and Schizophrenia

Journal of clinical psychopharmacology, 2013-06, Vol.33 (3), p.425-431

2013

Volltextzugriff (PDF)

CARDIAC BIOMARKERS IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS AS DOCUMENTED IN THAOS: THE TRANSTHYRETIN AMYLOIDOSIS SURVEY

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E1244-E1244

2013

Volltextzugriff (PDF)

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies

Human psychopharmacology, 2011-06, Vol.26 (4-5), p.282-290

2011

Volltextzugriff (PDF)

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection

The journal of clinical psychiatry, 2012-11, Vol.73 (11), p.1420

2012

Volltextzugriff (PDF)

Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales

The international journal of neuropsychopharmacology, 2015-11, Vol.18 (12), p.pyv064

2015

Volltextzugriff (PDF)

Ziprasidone and the Corrected QT Interval: A Comprehensive Summary of Clinical Data

CNS drugs, 2012-04, Vol.26 (4), p.351-365

2012

Volltextzugriff (PDF)

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies: RESPONSE TO ANTIPSYCHOTICS IN SCHIZOPHRENIA

Human psychopharmacology, 2011-06, Vol.26 (4-5), p.282-290

2011

Volltextzugriff (PDF)

Ziprasidone and the Corrected QT Interval

CNS drugs, 2012-04, Vol.26 (4), p.351

2012

Volltextzugriff (PDF)

Cigarette smoking and rheumatoid arthritis severity

Annals of the rheumatic diseases, 1997-08, Vol.56 (8), p.463-469

1997

Volltextzugriff (PDF)

Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder

Journal of psychiatric practice, 2011-03, Vol.17 (2), p.100

2011

Volltextzugriff (PDF)

Reply to Comments by Dr Hashimoto

Journal of clinical psychopharmacology, 2009-08, Vol.29 (4), p.412

2009

Volltextzugriff (PDF)

Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC)

Pharmacoepidemiology and drug safety, 2011-11, Vol.20 (11), p.1192-1198

2011

Volltextzugriff (PDF)

Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism

The Annals of pharmacotherapy, 2006-01, Vol.40 (1), p.32

2006

Volltextzugriff (PDF)

Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities

Arthritis and rheumatism, 1996-10, Vol.39 (10), p.1711-1719

1996

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Adult
(13)
Female
(13)
Psychiatry
(13)
Male
(12)
Middle Aged
(12)
Pharmacology & Pharmacy
(11)
Pharmacology. Drug Treatments
(11)
Piperazines - Therapeutic Use
(9)
Thiazoles - Therapeutic Use
(9)
Treatment Outcome
(9)
Dose-Response Relationship, Drug
(8)
Double-Blind Method
(8)
Neuropharmacology
(8)
Piperazines - Adverse Effects
(8)
Psychology. Psychoanalysis. Psychiatry
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression

Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

A Confidence Interval for the Maximal Mean QT Interval Change Caused by Drug Effect

Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression: Did Baseline Characteristics Impact Trial Outcome?

Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial

Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials

Comparative efficacy of antidepressants in preventing relapse in anxiety disorders — A meta-analysis

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial

Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis

Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, and Schizophrenia

CARDIAC BIOMARKERS IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS AS DOCUMENTED IN THAOS: THE TRANSTHYRETIN AMYLOIDOSIS SURVEY

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection

Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales

Ziprasidone and the Corrected QT Interval: A Comprehensive Summary of Clinical Data

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies: RESPONSE TO ANTIPSYCHOTICS IN SCHIZOPHRENIA

Ziprasidone and the Corrected QT Interval

Cigarette smoking and rheumatoid arthritis severity

Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder

Reply to Comments by Dr Hashimoto

Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC)

Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism

Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities

Suchergebnisse filtern